Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction
Why the study?
Does levosimendan improve mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction?
Population
94 consecutive patients with cardiogenic shock due to ST-elevation myocardial infarction from Swedish…
Comparison
Levosimendan (mandatory use policy, n=46) vs No levosimendan (contraindicated policy, n=48)
Design
Cohort
Follow-up
1 year
Authors
Discussion
Loading...
Member takes
Implication
Should not prompt routine levosimendan use in STEMI cardiogenic shock; leaves open confirmation via randomized trials.
Structured PICO
Does levosimendan improve mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction?
P
Population
94 consecutive patients with cardiogenic shock due to ST-elevation myocardial infarction (STEMI) from Swedish registries
I
Intervention
Levosimendan (mandatory use policy, n=46)
C
Comparator
No levosimendan (contraindicated policy, n=48)
O
Outcome
Adjusted mortality at 30 days and at one yearhard clinical
Routine use of levosimendan in patients with cardiogenic shock complicating STEMI does not appear to impact short- or long-term mortality.
Cite This Study
Elmir Ömerovic (2010) studied this question.